Shijiazhuang Yiling Pharmaceutical Co., Ltd.
以岭药业
002603
Shenzhen Stock Exchange
Company Profile
Academician Yiling Wu, lifetime honorary chairman, is a well-known Chinese medicine cardiologist and chief scientist of the Two National 973 Program. For many years, academician Yiling Wu led the team to ameliorate Collaterals Disease Theory, established the new drug R&D innovation system guided by the Collaterals Disease Theory, explore new ways to treat the major diseases guided by the Collaterals Disease Theory. A series of effective drugs have been developed for cardiovascular diseases, diabetes, tumors and avian influenza.The core competitive advantage of the company lies in the professional academic promotion mode guided by the Collateral Disease Theory. The Collateral Disease Theory is one of the core competitiveness of the company. It has a strong differentiation advantage and can greatly improve the cognition of the product. Company sales staff through its in-depth knowledge of products and professional promotion experience to carry out terminal promotion. Company's patent TCM products are new developed products guided by the Collateral Disease Theory with the exact clinical curative effect. The patented TCM products have been evaluated by the internationally recognized method of evidence-based medicine to make authoritative evaluation of their clinical curative effect, thus forming the unique advantage of academic promotion. At the same time, with the help of various academic conferences, the promotion of the characteristic advantages of patent products and the promotion of clinical doctors' recognition will lead to the rapid growth of sales.
Full description
Yiling pharmaceutical Ltd.(hereinafter referred to as Yiling) is a National Key High-tech Enterprise. Yiling was founded by Mr.Wu Yiling (Member of Chinese Academy of Engineering) in 1992; Powdered by Science and Technology, oriented to the market, Yiling has established a unique five-in-one operation model of "theory - clinical - R&D - industry - education". Yiling has established Shijiazhuang Bio-medicine Academician Workstation and National Key Laboratory of Collateral Vessels Disease Research and Innovative Chinese Herbs, built a new drug R&D system guided by Collateral Vessels Disease Innovation Theory, and owned a high-caliber R&D and management team. Yiling has won six National Awards, the Ho Leung Ho Lee Foundation Award and multiple Provincial Awards, it has undertaken and completed more than 30 national and provincial scientific researches projects, including the national " 973 " and " 863 " plans, the National Natural Science Foundation, and the "Twelfth Five-Year" key new drug creation special project, and has obtained more than 400 domestic and foreign invention patents. Yiling’s main business is the R&D, production and sales of patented innovative Chinese Herbs. Meanwhile, Yiling is actively deploying the chemical & biological medicine and health industries, and has established a medical and health industry pattern featuring the coordinated development and mutual promotion of innovative Chinese Herbs, chemical & biological medicine and the health industry. In the patented Chinese Herbs sector, Yiling has formed a unique advantage in guiding clinical major diseases and respiratory infectious diseases treatment research with Collateral Vessels Disease Innovation Theory, that drives the R&D technological core competitiveness, and has established a new drug R&D system with independent intellectual property rights, and its scientific and technological innovation ability ranks among the forefront of the Chinese Herb Industry. Focusing on the six major diseases with high incidence and large amount of drugs used, including cardiovascular disease/diabetes/respiratory/tumor/nerve/urinary, a series of innovation Chinese Herbs have been developed, and unique products have been formed in the pharmaceutical industry. Currently Yiling has owned 13 patented new drugs , covering the fields of cardio-cerebrovascular diseases, respiratory, diabetes, tumors, nerves, urinary and other clinically frequently-occurring and major diseases. In the chemical&biological medicine sector, Yiling adheres to the strategy of "Plunging into by C(D)MO - Activating international and domestic registration of generic drugs together - Settling the layout of new drug’s R&D, production and market”. Workshops have been approved GMP inspections conducted by US FDA , EMA and other international authorities. Yiling holds international and domestic registration together, and has received 12 ANDAs from US FDA. Yiling is also focusing on R&D of innovative drugs, until now 4 first-grade innovative drugs have walking into the clinical stage, one of them has been entered the stage of applying for production approval; except these, there are more innovative drugs in the preclinical research stage. In the health industry sector, Yiling relies on the theoretical innovation, scientific research innovation advantages and thorough medical and industrial resources, all that are accumulated in more than 20 years of development, and takes "health needs management, fitness needs operation" as the innovative concept, fully explores the quintessence of traditional Chinese health preservation theory, merges modern technology, then carries out a full range of health products research and development, sales and health management services.